The Impact of the SCN9A Gene Polymorphism on Postoperative Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-08-31

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to determine the association between postoperative pain after cesarean section and several single nucleotide polymorphisms in SCN9A sodium channels gene.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

SCN9A gene encodes an alpha subunit of the voltage-gated sodium channel (Nav1.7) and polymorphisms of this gene are associated with severe pain disorders. The impact of the polymorphisms in SCN9A on postoperative pain and opioid consumption after cesarean section is unclear.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Pregnancy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

NAV1.7 Voltage-Gated Sodium Channel pain, postoperative cesarean section

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cesarean section

Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique

Intervention Type PROCEDURE

Opioid Tramadol

Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tramadol (contramal)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The women aged 18 to 45,
* in 36 to 40 weeks of pregnancy
* undergoing cesarean section

Exclusion Criteria

* History of chronic pain or pain disorders
* Psychiatric diseases
* Diabetes mellitus
* Severe cardiovascular, kidney or liver diseases
* Alcohol or drug abuse
* Heavy smoker
* Unable to use the Patient controlled analgesia (PCA) pump

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tuğba Karaman

Assistant Professor, M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tugba Karaman, M.D.

Role: PRINCIPAL_INVESTIGATOR

Gaziosmanpasa University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gaziosmanpasa University Medical School Hospital

Tokat Province, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GEN-S

Identifier Type: -

Identifier Source: org_study_id